Sec Form 3 Filing - Bruno Julianne @ CRISPR Therapeutics AG - 2024-05-23

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Bruno Julianne 2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Operating Officer (Last) (First) (Middle) C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET 3. Date of Earliest Transaction (MM/DD/YY) 05/23/2024 (Street) BOSTON, MA02127 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 3,111 D Common Shares 7,088 I By Julianne Bruno 2022 GRAT ( 1 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 38.82 ( 2 ) 05/01/2029 Common Shares 10,000 D Stock Option (Right to Buy) $ 39 ( 3 ) 10/22/2029 Common Shares 2,200 D Stock Option (Right to Buy) $ 44.67 ( 4 ) 03/10/2030 Common Shares 3,105 D Stock Option (Right to Buy) $ 86.75 ( 5 ) 10/05/2030 Common Shares 1,800 D Stock Option (Right to Buy) $ 133.88 ( 6 ) 03/11/2031 Common Shares 4,719 D Stock Option (Right to Buy) $ 97 ( 7 ) 10/15/2031 Common Shares 1,966 D Stock Option (Right to Buy) $ 58.29 ( 8 ) 02/18/2032 Common Shares 6,000 D Stock Option (Right to Buy) $ 61.65 ( 9 ) 10/07/2032 Common Shares 4,000 D Stock Option (Right to Buy) $ 43.22 ( 10 ) 03/10/2033 Common Shares 15,333 D Stock Option (Right to Buy) $ 44.31 ( 11 ) 10/13/2033 Common Shares 10,000 D Stock Option (Right to Buy) $ 72.94 ( 12 ) 03/20/2034 Common Shares 20,000 D Restricted Stock Units ( 14 ) ( 13 ) ( 13 ) Common Shares 435 D Restricted Stock Units ( 14 ) ( 15 ) ( 15 ) Common Shares 7,000 D Restricted Stock Units ( 14 ) ( 16 ) ( 16 ) Common Shares 1,300 D Restricted Stock Units ( 14 ) ( 17 ) ( 17 ) Common Shares 8,500 D Restricted Stock Units ( 14 ) ( 18 ) ( 18 ) Common Shares 7,195 D Restricted Stock Units ( 14 ) ( 19 ) ( 19 ) Common Shares 20,000 D Restricted Stock Units ( 14 ) ( 20 ) ( 20 ) Common Shares 15,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Bruno Julianne C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET BOSTON, MA02127 Chief Operating Officer Signatures /s/ Julianne Bruno 05/23/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Shares held by Julianne Bruno 2022 GRAT, a grantor retained annuity trust of which the Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein, if any. ( 2 )This option was granted on May 1, 2019 with respect to 10,000 Common Shares. 25% of the shares vested on May 1, 2020, with the remaining shares vested in 36 equal monthly installments thereafter. ( 3 )This option was granted on October 22, 2019 with respect to 2,200 Common Shares. 100% of the shares vested in 48 equal monthly installments, with the first installment vested on November 22, 2019. ( 4 )This option was granted on March 10, 2020 with respect to 3,105 Common Shares. 100% of the shares vested in 48 equal monthly installments, with the first installment vested on April 10, 2020. ( 5 )This option was granted on October 5, 2020 with respect to 1,800 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 5, 2020. ( 6 )This option was granted on March 11, 2021 with respect to 4,719 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 11, 2021. ( 7 )This option was granted on October 15, 2021 with respect to 1,966 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 15, 2021. ( 8 )This option was granted on February 18, 2022 with respect to 6,000 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on March 18, 2022. ( 9 )This option was granted on October 7, 2022 with respect to 4,000 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 7, 2022. ( 10 )This option was granted on March 10, 2023 with respect to 15,333 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 10, 2023. ( 11 )This option was granted on October 13, 2023 with respect to 10,000 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on November 13, 2023. ( 12 )This option was granted on March 20, 2024 with respect to 20,000 Common Shares. 100% of the shares vest in 48 equal monthly installments, with the first installment vested on April 20, 2024. ( 13 )This restricted stock unit award was granted on March 11, 2021 with respect to 1,740 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. ( 14 )Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. ( 15 )This restricted stock unit award was granted on December 14, 2021 with respect to 7,000 Common Shares, with 100% of the shares vesting on June 20, 2024. ( 16 )This restricted stock unit award was granted on February 18, 2022 with respect to 2,600 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026. ( 17 )This restricted stock unit award was granted on December 22, 2022 with respect to 8,500 Common Shares, with 100% of the shares vesting on June 22, 2025. ( 18 )This restricted stock unit award was granted on March 10, 2023 with respect to 9,593 Common Shares, with (i) one quarter of the shares vesting on March 10, 2024, (ii) one quarter of the shares vesting on March 10, 2025, (iii) one quarter of the shares vesting on March 10, 2026, and (iv) one quarter of the shares vesting on March 10, 2027. ( 19 )This restricted stock unit award was granted on September 15, 2023 with respect to 20,000 Common Shares, with 100% of the shares vesting on September 15, 2025. ( 20 )This restricted stock unit award was granted on March 20, 2024 with respect to 15,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028.

Remarks: Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.